Tech Company Financing Transactions
Theraclone Sciences Funding Round
Amgen Ventures, Arch Venture Partners and MPM Capital participated in a $800 thousand funding round for Theraclone Sciences. The round closed on 3/31/2005.
Transaction Overview
Company Name
Announced On
3/31/2005
Transaction Type
Venture Equity
Amount
$800,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1124 Columbia St. 300
Seattle, WA 98104
USA
Seattle, WA 98104
USA
Phone
Website
Email Address
Overview
Theraclone Sciences is a discovery-stage biotech developing novel therapeutic antibodies for the treatment of infectious disease and inflammation. Our proprietary discovery platform allows us to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clifford Stocks
Chief Financial Officer
Russ Hawkinson
Chief Scientific Officer
Kristine Swiderek
Browse more venture capital transactions:
Prev: 3/31/2005: Infotone Communications venture capital transaction
Next: 3/31/2005: InMage Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs